166 related articles for article (PubMed ID: 22483312)
1. Targeting Parkinson's - tyrosine hydroxylase and oxidative stress as points of interventions.
Khan MS; Tabrez S; Priyadarshini M; Priyamvada S; Khan MM
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):369-80. PubMed ID: 22483312
[TBL] [Abstract][Full Text] [Related]
2. Overview of tyrosine hydroxylase in Parkinson's disease.
Zhu Y; Zhang J; Zeng Y
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):350-8. PubMed ID: 22483316
[TBL] [Abstract][Full Text] [Related]
3. The function of tyrosine hydroxylase in the normal and Parkinsonian brain.
Tolleson C; Claassen D
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):381-6. PubMed ID: 22483314
[TBL] [Abstract][Full Text] [Related]
4. Redox sensitivity of tyrosine hydroxylase activity and expression in dopaminergic dysfunction.
Di Giovanni G; Pessia M; Di Maio R
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):419-29. PubMed ID: 22483306
[TBL] [Abstract][Full Text] [Related]
5. Effect of siRNA-induced silencing of cellular prion protein on tyrosine hydroxylase expression in the substantia nigra of a rat model of Parkinson's disease.
Wang X; Yang HA; Wang XN; Du YF
Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27173342
[TBL] [Abstract][Full Text] [Related]
6. Enzymatic stimulation and enzymatic inhibition in Parkinson's disease.
Nagatsu T
Acta Neurol Scand Suppl; 1993; 146():14-7. PubMed ID: 8101411
[TBL] [Abstract][Full Text] [Related]
7. Moving beyond tyrosine hydroxylase to define dopaminergic neurons for use in cell replacement therapies for Parkinson's disease.
White RB; Thomas MG
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):340-9. PubMed ID: 22483315
[TBL] [Abstract][Full Text] [Related]
8. A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.
Tabrez S; Jabir NR; Shakil S; Greig NH; Alam Q; Abuzenadah AM; Damanhouri GA; Kamal MA
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):395-409. PubMed ID: 22483313
[TBL] [Abstract][Full Text] [Related]
9. Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease.
Shen Y; Muramatsu SI; Ikeguchi K; Fujimoto KI; Fan DS; Ogawa M; Mizukami H; Urabe M; Kume A; Nagatsu I; Urano F; Suzuki T; Ichinose H; Nagatsu T; Monahan J; Nakano I; Ozawa K
Hum Gene Ther; 2000 Jul; 11(11):1509-19. PubMed ID: 10945765
[TBL] [Abstract][Full Text] [Related]
10. A brief overview of tyrosine hydroxylase and α-synuclein in the Parkinsonian brain.
Khan W; Priyadarshini M; Zakai HA; Kamal MA; Alam Q
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):456-62. PubMed ID: 22583430
[TBL] [Abstract][Full Text] [Related]
11. Tyrosine hydroxylase (TH), its cofactor tetrahydrobiopterin (BH4), other catecholamine-related enzymes, and their human genes in relation to the drug and gene therapies of Parkinson's disease (PD): historical overview and future prospects.
Nagatsu T; Nagatsu I
J Neural Transm (Vienna); 2016 Nov; 123(11):1255-1278. PubMed ID: 27491309
[TBL] [Abstract][Full Text] [Related]
12. Mitochondria as an easy target to oxidative stress events in Parkinson's disease.
Reale M; Pesce M; Priyadarshini M; Kamal MA; Patruno A
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):430-8. PubMed ID: 22483310
[TBL] [Abstract][Full Text] [Related]
13. Prevention of 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced nitration of tyrosine hydroxylase and neurotoxicity by EUK-134, a superoxide dismutase and catalase mimetic, in cultured dopaminergic neurons.
Pong K; Doctrow SR; Baudry M
Brain Res; 2000 Oct; 881(2):182-9. PubMed ID: 11036157
[TBL] [Abstract][Full Text] [Related]
14. Human tyrosine hydroxylase in Parkinson's disease and in related disorders.
Nagatsu T; Nakashima A; Ichinose H; Kobayashi K
J Neural Transm (Vienna); 2019 Apr; 126(4):397-409. PubMed ID: 29995172
[TBL] [Abstract][Full Text] [Related]
15. Tyrosine hydroxylase and Parkinson's disease.
Haavik J; Toska K
Mol Neurobiol; 1998 Jun; 16(3):285-309. PubMed ID: 9626667
[TBL] [Abstract][Full Text] [Related]
16. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism.
Zhang Y; Calon F; Zhu C; Boado RJ; Pardridge WM
Hum Gene Ther; 2003 Jan; 14(1):1-12. PubMed ID: 12573054
[TBL] [Abstract][Full Text] [Related]
17. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter.
Zhang Y; Schlachetzki F; Zhang YF; Boado RJ; Pardridge WM
Hum Gene Ther; 2004 Apr; 15(4):339-50. PubMed ID: 15053859
[TBL] [Abstract][Full Text] [Related]
18. Gene therapy of Parkinson's disease using adeno-associated virus (AAV) vectors.
Ozawa K; Fan DS; Shen Y; Muramatsu S; Fujimoto K; Ikeguchi K; Ogawa M; Urabe M; Kume A; Nakano I
J Neural Transm Suppl; 2000; (58):181-91. PubMed ID: 11128607
[TBL] [Abstract][Full Text] [Related]
19. Nitration of soluble proteins in organotypic culture models of Parkinson's disease.
Larsen TR; Söderling AS; Caidahl K; Roepstorff P; Gramsbergen JB
Neurochem Int; 2008 Feb; 52(3):487-94. PubMed ID: 17900761
[TBL] [Abstract][Full Text] [Related]
20. Current status of tyrosine hydroxylase in management of Parkinson's disease.
Feve AP
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):450-5. PubMed ID: 22583428
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
